All Articles in: Boston Scientific

Vagus Nerve Stimulation Study Misses Primary Efficacy Endpoint, But QOL ImprovedSeptember 1, 2014

It’s good news/bad news for Boston Scientific’s Vagus Nerve Stimulation plans as a heart failure therapy. While efficacy endpoints suggested no outcome improvement, patients in the treatment group of the sham controlled study reported quality of life improvement.

Posted in: , ,

Boston Scientific and ASAHI INTECC Join Forces on FFR Wire ProjectAugust 19, 2014

Sounds like a plan. Combine the offerings of one of the Cardiovascular big boys with wire forming company’s expertise and FFR technology is likely to benefit.

Posted in: , ,

CE Mark for Boston Scientific’s Agent™ Drug-Coated Coronary BalloonJuly 30, 2014

Boston Scientific’s Agent™ Paclitaxel-Coated PTCA Balloon Catheter has gained CE mark approval and will now be launched in Europe.

Posted in: , ,

FDA Approves Boston Scientific’s REBEL™ Coronary StentJuly 22, 2014

U.S. FDA approval of REBEL™ Platinum Chromium Coronary Stent brings the benefits of modern stent architecture to patients not suitable for drug eluting variants.

Posted in: , ,

Boston Scientific Plugs TAVI Gap with CE Mark for 25 mm Lotus™July 15, 2014

Boston Scientific’s Lotus™ TAVI System has been enhanced by the addition of a 25mm variant to its CE marked portfolio.

Posted in: , ,

CE Mark for Boston Scientific’s Ranger™ Drug-Coated BalloonJuly 14, 2014

Boston Scientific Corporation has received CE Mark for the Ranger™ Paclitaxel-Coated PTA Balloon Catheter which is now to be fully launched in Europe.

Posted in: , ,

One-Year Results Back Up Vercise™ DBS System in ParkinsonsJune 12, 2014

One year data demonstrate highly significant improvement in motor function for patients with Parkinson’s Disease when treated with Boston Scientific’s Vercise DBS system

Posted in: , ,

Boston Scientific Touts Positive 6 Month Data from Lotus™ TAVI StudyMay 27, 2014

New data presented at EuroPCR 2014 in Paris suggests impressive performance at six months for the Lotus™ Valve System, with 79.8 percent of patients showing no paravalvular aortic regurgitation at six months with no cases of severe paravalvular aortic regurgitation in any patient.

Posted in: , , ,

Another Back Pain Study Supports Boston’s Precision Spectra™ Spinal Cord StimulatorMay 9, 2014

New retrospective data presented at the World Institute of Pain (WIP) 7th World Congress demonstrates that Boston Scientific’s Precision Spectra™ Spinal Cord Stimulator (SCS) System provided sustained and highly significant relief of low-back pain six months after implantation.

Posted in: , , ,

ICD Study Says Defibrillation Testing Safe But Unneccessary

A new, randomized study, supported by Boston Scientific, presented at this year’s HRS event suggests that ICD patients do equally well, regardless of whether their implant was defib tested at the time of implantation.

Posted in: , ,

FDA Green Light for Boston Scientific’s New Defibrillators and Heart Failure DevicesApril 16, 2014

Boston Scientific Corporation has received FDA approval for its latest generation of defibrillators and heart failure devices, including the DYNAGEN™ MINI and INOGEN™ MINI ICDs, as well as the DYNAGEN™ X4 and INOGEN™ X4 CRT-Ds.

Posted in: , ,

FDA and CE Nods for Boston’s Expect™ Slimline (SL) Needle for Fine Needle Aspiration During Endoscopic UltrasoundApril 8, 2014

Boston Scientific Corporation has received U.S. FDA clearance and CE Mark approval in Europe for the Expect™ Slimline (SL) Needle, which means it is now globally available for Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) procedures.

Posted in: , , , ,

Boston Scientific’s TAVI Data Stands Up to Big TwoApril 3, 2014

While Edwards Lifesciences and Medtronic slugged it out at ACC 2014 with studies comparing their TAVI (transcatheter aortic valve implantation)offerings, Boston Scientific draws our attention to new data presented at the event that says its own Lotus™ Valve System continued to demonstrate impressive performance at three months.

Posted in: , , ,

Registry Data Supports Boston Scientific S-ICD™ SystemApril 1, 2014

Boston Scientific points us at a new publication that details registry data relating to the real world performance of the company’s S-ICD (Subcutaneous Implantable Cardioverter/Defibrillator) and finds the device does the job.

Posted in: , ,

CE Mark Approval and First Implants of Boston Scientific’s Ingevity™ MRI Pacing LeadsMarch 14, 2014

Boston Scientific Corporation has announced CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance imaging (MRI) compatible pacing leads.

Posted in: , ,

CE Mark for Boston Scientific’s REBEL™ Platinum Chromium Coronary StentMarch 13, 2014

Boston Scientific Corporation has received CE Mark approval for the REBEL™ Platinum Chromium Coronary Stent System, the company’s latest generation bare metal stent for the treatment of coronary artery disease (CAD). Background CAD, a narrowing of blood vessels that supply …

Posted in: , ,

<< Previous Articles